Abstract
Background Despite an increasingly diverse population, knowledge regarding racial and ethnic disparities is limited among women and men undergoing atherosclerotic cardiovascular (ASCVD) screening. Our aim was to compare CV mortality by ASCVD risk and coronary artery calcium (CAC) scores among Black and Hispanic women and men compared to other participants.
Design and Methods From the CAC Consortium, 42,964 participants with self-reported race and ethnicity were followed for a median of 11.7 years. Multivariable Cox proportional hazards regression models were used to estimate CV mortality, with separate analyses by sex.
Results One-third of enrollees were women; 977 self-reported as Black, 1,349 as Hispanic, 1,621 as Asian, and 740 as American Indian/Native Alaskan/Hawaiian or other; the remainder were white. Black women and men had higher ASCVD risk and CAC scores yielding the highest CV mortality compared to other participants. Among Black women and men with a 0 CAC or ASCVD risk score <5%, hazard ratios (HRs) were 6-9-fold higher than that of other women and men. In men with CAC scores ≥100, Black men (HR: 4.2,p<0.001) had the highest CV mortality compared to all other men. A similar high-risk pattern was noted for Black women with CAC scores ≥100 (p<0.001), even when adjusting for the ASCVD risk score. Overall, Hispanics had an elevated CV mortality, higher than others but less than that of Black participants. Patterns of intermediate risk were notable for Hispanic men with a CAC score of 0 (HR=3.6, p=0.006) and ≥100 (HR=2.3, p=0.03).
Conclusions The disproportionately high and excess CV mortality among Black women and men represents significant barriers to reducing the burden of ASCVD through effective screening using ASCVD risk and CAC scores.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All sites and database analysis are overseen by continuing IRB review and approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available upon request and submission of specific aims.
